دورية أكاديمية
Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.
| العنوان: | Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification. |
|---|---|
| المؤلفون: | Patel JN; Department of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, Charlotte, NC 28204, USA.; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA., Singh J; Sanger Heart and Vascular Institute, Atrium Health, Charlotte, NC 28204, USA., Ghosh N; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA.; Department of Hematologic Malignancies and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC 28204, USA. |
| المصدر: | Oncotarget [Oncotarget] 2024 Jun 03; Vol. 15, pp. 355-359. Date of Electronic Publication: 2024 Jun 03. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Electronic Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
| مواضيع طبية MeSH: | Agammaglobulinaemia Tyrosine Kinase*/antagonists & inhibitors , Agammaglobulinaemia Tyrosine Kinase*/genetics , Protein Kinase Inhibitors*/adverse effects , Cardiotoxicity*/etiology , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/genetics , Piperidines*/adverse effects , Piperidines*/therapeutic use, Humans ; Adenine/analogs & derivatives ; Adenine/adverse effects ; Risk Assessment ; Pyrimidines/adverse effects ; Pyrazoles/adverse effects ; Biomarkers ; Polymorphism, Single Nucleotide ; KCNQ1 Potassium Channel/genetics ; Tyrosine Kinase Inhibitors |
| مستخلص: | Ibrutinib was the first Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of patients with chronic lymphocytic leukemia (CLL). While producing durable responses and prolonging survival, roughly 20-25% of patients experience dose limiting side effects, mostly consisting of cardiovascular toxicities like severe hypertension and atrial fibrillation. While clinical predictors of BTK inhibitor-related cardiotoxicity have been proposed and may aid in risk stratification, there is no routine risk model used in clinical practice today to identify patients at highest risk. A recent study investigating genetic predictors of ibrutinib-related cardiotoxicity found that single nucleotide polymorphisms in KCNQ1 and GATA4 were significantly associated with cardiotoxic events. If replicated in larger studies, these biomarkers may improve risk stratification in combination with clinical factors. A clinicogenomic risk model may aid in identifying patients at highest risk of developing BTK inhibitor-related cardiotoxicity in which further risk mitigation strategies may be explored. |
| References: | Circulation. 2021 Jul 20;144(3):e41-e55. (PMID: 34134525) Chronic Dis Transl Med. 2020 Jan 17;5(4):214-220. (PMID: 32055780) Blood Adv. 2022 Sep 27;6(18):5516-5525. (PMID: 35790105) Blood Adv. 2017 Sep 08;1(20):1739-1748. (PMID: 29296820) Circ Genom Precis Med. 2020 Aug;13(4):e000067. (PMID: 32698598) N Engl J Med. 2015 Dec 17;373(25):2425-37. (PMID: 26639149) Curr Cardiol Rep. 2023 Aug;25(8):863-878. (PMID: 37493874) JACC CardioOncol. 2022 Sep 20;4(3):302-312. (PMID: 36213359) Clin Cancer Res. 2023 Dec 1;29(23):4941-4948. (PMID: 37738027) Leuk Lymphoma. 2017 Jul;58(7):1630-1639. (PMID: 27885886) Circulation. 2020 Dec 22;142(25):2443-2455. (PMID: 33092403) Haematologica. 2018 May;103(5):874-879. (PMID: 29419429) JACC Clin Electrophysiol. 2018 Dec;4(12):1491-1500. (PMID: 30573111) Leuk Lymphoma. 2019 Jun;60(6):1447-1453. (PMID: 30730240) PLoS One. 2019 Feb 20;14(2):e0211228. (PMID: 30785921) JACC CardioOncol. 2023 Feb 07;5(3):402-405. (PMID: 37397087) Hematol Oncol. 2023 Aug;41(3):363-370. (PMID: 36762406) Clin Cancer Res. 2017 Jun 1;23(11):2831-2841. (PMID: 27903679) J Clin Oncol. 2023 Jun 1;41(16):2911-2925. (PMID: 36730884) |
| فهرسة مساهمة: | Keywords: BTK inhibitor; biomarkers; cardiotoxicity; genetics; risk |
| المشرفين على المادة: | EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase) 0 (Protein Kinase Inhibitors) 1X70OSD4VX (ibrutinib) 0 (Piperidines) JAC85A2161 (Adenine) 0 (Pyrimidines) 0 (Pyrazoles) EC 2.7.10.2 (BTK protein, human) 0 (Biomarkers) 0 (KCNQ1 Potassium Channel) 0 (Tyrosine Kinase Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240603 Date Completed: 20240603 Latest Revision: 20240605 |
| رمز التحديث: | 20240605 |
| مُعرف محوري في PubMed: | PMC11146632 |
| DOI: | 10.18632/oncotarget.28589 |
| PMID: | 38829647 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.28589 |